


Enfortumab vedotin EV-103/KEYNOTE-869

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



>30% grade 3-4 toxicities impacting well being



#### Other adjustments



Enfortumab vedotin EV-103/KEYNOTE-869

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: For patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Experimental Arm: Enfortumab vedotin + Pembrolizumab

Control Arm: Single arm



